Lupin inks research pact with CSIR-NCL, DST
09 March 2018 | News
Through this research collaboration, CSIR-NCL and Lupin would together work towards the development of a novel continuous purification process for manufacturing mAb therapeutics.
Image credit- diaglobal.org
Lupin has entered into an agreement with CSIR-National Chemical Laboratory (CSIR-NCL, Pune) and Department of Science and Technology, (DST, Delhi) for conducting research on a continuous purification process development of a biosimilar monoclonal antibody therapeutic (mAb).
With an increasing demand for biosimilar therapeutics and an ever-increasing pressure for manufacturing cost reduction with quality maintenance, the biopharmaceutical industry is showing keen interest in the development of continuous manufacturing processes.
Through this research collaboration, CSIR-NCL and Lupin would together work towards the development of a novel continuous purification process for manufacturing mAb therapeutics. Biopharmaceuticals, biologics and monoclonal antibodies are the next wave of discovery and innovation in new pharmaceuticals.
